HC Wainwright Analysts Raise Earnings Estimates for FULC

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Research analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a note issued to investors on Tuesday, February 24th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.28) per share for the quarter, up from their previous forecast of ($0.29). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at ($1.26) EPS, FY2028 earnings at $0.87 EPS and FY2029 earnings at $1.79 EPS.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.31) EPS for the quarter, hitting the consensus estimate of ($0.31).

A number of other analysts also recently issued reports on the stock. Leerink Partners restated an “outperform” rating on shares of Fulcrum Therapeutics in a report on Tuesday. Piper Sandler reiterated an “overweight” rating and issued a $23.00 price objective (up from $16.00) on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Royal Bank Of Canada lifted their target price on Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a research report on Monday, December 8th. Cantor Fitzgerald increased their price target on Fulcrum Therapeutics from $15.00 to $24.00 and gave the stock an “overweight” rating in a report on Monday, December 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Fulcrum Therapeutics Trading Down 4.0%

Fulcrum Therapeutics stock opened at $8.38 on Thursday. The company has a 50-day moving average price of $10.58 and a 200 day moving average price of $9.49. Fulcrum Therapeutics has a 12-month low of $2.32 and a 12-month high of $15.74. The stock has a market cap of $558.11 million, a P/E ratio of -7.10 and a beta of 3.19.

Insider Activity

In related news, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total value of $178,050.00. Following the completion of the sale, the director directly owned 469,864 shares of the company’s stock, valued at $5,577,285.68. The trade was a 3.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of Fulcrum Therapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the sale, the insider owned 6,053,960 shares in the company, valued at $84,634,360.80. This trade represents a 40.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Fulcrum Therapeutics in the fourth quarter valued at approximately $30,000. Quarry LP purchased a new stake in Fulcrum Therapeutics in the 3rd quarter valued at $35,000. Meeder Asset Management Inc. acquired a new position in Fulcrum Therapeutics in the fourth quarter valued at $39,000. Russell Investments Group Ltd. raised its holdings in shares of Fulcrum Therapeutics by 4,209.3% in the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after buying an additional 9,092 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of Fulcrum Therapeutics by 108.3% in the third quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after buying an additional 3,697 shares during the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

Key Fulcrum Therapeutics News

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Positive Sentiment: HC Wainwright raised several near-term quarterly EPS estimates (Q1–Q4 2026 now ~($0.28) vs prior ($0.29)) and reiterated a “Buy” rating with a $25 price target — a supportive catalyst that signals analyst confidence in execution and potential upside. HC Wainwright research note (MarketBeat)
• Neutral Sentiment: Research summaries setting FY2030 expectations were published, which provide longer-horizon modeling context but did not contain immediate new clinical or commercial milestones likely to move the stock sharply on their own. Research Analysts Set Expectations for FULC FY2030 Earnings
• Negative Sentiment: Independent commentary (Seeking Alpha) highlighted a strong fetal hemoglobin (HbF) signal but concluded the total addressable market (TAM) appears narrower than some investors hoped, leading to a “Hold” stance — this reduces bullish conviction and weighs on the stock. Fulcrum: Strong HbF Signal, Narrow TAM, Same ‘Hold’ Conclusion
• Negative Sentiment: While HC Wainwright raised near-term estimates, it trimmed FY2028–FY2029 EPS forecasts (FY2028 to $0.87 from $0.94; FY2029 to $1.79 from $1.91), which limits some of the long-term upside baked into the $25 target and may temper enthusiasm. HC Wainwright forecast changes (MarketBeat)

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.